6 days Ago By ABMN Staff
Alliancebernstein L.P. increased its stake in Cogent Biosciences, Inc.
( NASDAQ:COGT – Free Report ) by 466.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 464,942 shares of the technology company’s stock after acquiring an additional 382,882 shares during the period.
Alliancebernstein L.P.’s holdings in Cogent Biosciences were worth $3,627,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Barclays PLC raised its position in Cogent Biosciences by 124.8% in the 3rd quarter.
Barclays PLC now owns 175,684 shares of the technology company’s stock valued at $1,897,000 after purchasing an additional 97,541 shares in the last quarter. Geode Capital Management LLC raised its holdings in Cogent Biosciences by 15.1% in the third quarter.
Geode Capital Management LLC now owns 2,280,793 shares of the technology company’s stock valued at $24,638,000 after acquiring an additional 300,062 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Cogent Biosciences by 10.5% in the fourth quarter.
New York State Common Retirement Fund now owns 23,102 shares of the technology company’s stock worth $180,000 after acquiring an additional 2,200 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Cogent Biosciences by 9.
7% in the third quarter. JPMorgan Chase & Co. now owns 64,828 shares of the technology company’s stock worth $700,000 after acquiring an additional 5,720 shares during the last quarter.
Finally, Wellington Management Group LLP grew its holdings in Cogent Biosciences by 8.0% during the 3rd quarter. Wellington Management Group LLP now owns 342,323 shares of the technology company’s stock worth $3,697,000 after acquiring an additional 25,470 shares in the last quarter.
Wall Street Analyst Weigh In A number of equities research analysts have recently weighed in on COGT shares. Robert W. Baird reduced their price objective on shares of Cogent Biosciences from $10.
00 to $8.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. HC Wainwright cut their price target on Cogent Biosciences from $17.
00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Wedbush reaffirmed a “neutral” rating and set a $11.
00 price objective on shares of Cogent Biosciences in a research report on Tuesday, February 25th. Scotiabank started coverage on Cogent Biosciences in a report on Friday, March 7th. They issued a “sector outperform” rating and a $17.
00 price objective on the stock. Finally, Piper Sandler upgraded Cogent Biosciences to a “strong-buy” rating in a research note on Friday, March 7th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock.
Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.43.
Cogent Biosciences Stock Up 7.5 % COGT opened at $4.58 on Tuesday.
The firm has a market cap of $521.43 million, a price-to-earnings ratio of -1.85 and a beta of 1.
67. Cogent Biosciences, Inc. has a 52 week low of $3.
72 and a 52 week high of $12.61. The business’s 50 day moving average is $6.
81 and its two-hundred day moving average is $8.56. About Cogent Biosciences ( Free Report ) Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Further Reading Want to see what other hedge funds are holding COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cogent Biosciences, Inc.
( NASDAQ:COGT – Free Report ). Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
